nodes	percent_of_prediction	percent_of_DWPC	metapath
Clindamycin—Skin scaly—Epirubicin—liver cancer	0.0343	0.0343	CcSEcCtD
Clindamycin—Hyperthyroidism—Sorafenib—liver cancer	0.0318	0.0318	CcSEcCtD
Clindamycin—Skin scaly—Doxorubicin—liver cancer	0.0317	0.0317	CcSEcCtD
Clindamycin—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.0214	0.0214	CcSEcCtD
Clindamycin—Folliculitis—Sorafenib—liver cancer	0.02	0.02	CcSEcCtD
Clindamycin—Diarrhoea haemorrhagic—Epirubicin—liver cancer	0.0184	0.0184	CcSEcCtD
Clindamycin—Diarrhoea haemorrhagic—Doxorubicin—liver cancer	0.017	0.017	CcSEcCtD
Clindamycin—Proteinuria—Sorafenib—liver cancer	0.0143	0.0143	CcSEcCtD
Clindamycin—Protein urine present—Sorafenib—liver cancer	0.0141	0.0141	CcSEcCtD
Clindamycin—Oesophageal ulcer—Epirubicin—liver cancer	0.0127	0.0127	CcSEcCtD
Clindamycin—Skin exfoliation—Sorafenib—liver cancer	0.012	0.012	CcSEcCtD
Clindamycin—Oesophageal ulcer—Doxorubicin—liver cancer	0.0118	0.0118	CcSEcCtD
Clindamycin—Haematochezia—Epirubicin—liver cancer	0.0115	0.0115	CcSEcCtD
Clindamycin—Fungal skin infection—Epirubicin—liver cancer	0.0111	0.0111	CcSEcCtD
Clindamycin—Haematochezia—Doxorubicin—liver cancer	0.0107	0.0107	CcSEcCtD
Clindamycin—Fungal skin infection—Doxorubicin—liver cancer	0.0103	0.0103	CcSEcCtD
Clindamycin—Dermatitis exfoliative—Sorafenib—liver cancer	0.00966	0.00966	CcSEcCtD
Clindamycin—Vaginal moniliasis—Epirubicin—liver cancer	0.0092	0.0092	CcSEcCtD
Clindamycin—Vulvovaginal candidiasis—Epirubicin—liver cancer	0.00883	0.00883	CcSEcCtD
Clindamycin—Vaginal moniliasis—Doxorubicin—liver cancer	0.00851	0.00851	CcSEcCtD
Clindamycin—Vulvovaginal mycotic infection—Epirubicin—liver cancer	0.00849	0.00849	CcSEcCtD
Clindamycin—Local reaction—Epirubicin—liver cancer	0.00838	0.00838	CcSEcCtD
Clindamycin—Dry skin—Sorafenib—liver cancer	0.00836	0.00836	CcSEcCtD
Clindamycin—Abdominal pain upper—Sorafenib—liver cancer	0.00833	0.00833	CcSEcCtD
Clindamycin—Vesiculobullous rash—Epirubicin—liver cancer	0.00828	0.00828	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.00821	0.00821	CcSEcCtD
Clindamycin—Vulvovaginal candidiasis—Doxorubicin—liver cancer	0.00817	0.00817	CcSEcCtD
Clindamycin—Vulvovaginal mycotic infection—Doxorubicin—liver cancer	0.00786	0.00786	CcSEcCtD
Clindamycin—Local reaction—Doxorubicin—liver cancer	0.00776	0.00776	CcSEcCtD
Clindamycin—Vesiculobullous rash—Doxorubicin—liver cancer	0.00766	0.00766	CcSEcCtD
Clindamycin—Pelvic pain—Epirubicin—liver cancer	0.00763	0.00763	CcSEcCtD
Clindamycin—Vaginal discharge—Epirubicin—liver cancer	0.00763	0.00763	CcSEcCtD
Clindamycin—Abdominal discomfort—Sorafenib—liver cancer	0.00755	0.00755	CcSEcCtD
Clindamycin—Folliculitis—Epirubicin—liver cancer	0.00738	0.00738	CcSEcCtD
Clindamycin—Neutropenia—Sorafenib—liver cancer	0.00737	0.00737	CcSEcCtD
Clindamycin—Pelvic pain—Doxorubicin—liver cancer	0.00706	0.00706	CcSEcCtD
Clindamycin—Vaginal discharge—Doxorubicin—liver cancer	0.00706	0.00706	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00697	0.00697	CcSEcCtD
Clindamycin—Redness—Epirubicin—liver cancer	0.00688	0.00688	CcSEcCtD
Clindamycin—Jaundice—Sorafenib—liver cancer	0.00685	0.00685	CcSEcCtD
Clindamycin—Folliculitis—Doxorubicin—liver cancer	0.00683	0.00683	CcSEcCtD
Clindamycin—Seborrhoeic dermatitis—Epirubicin—liver cancer	0.00681	0.00681	CcSEcCtD
Clindamycin—Epistaxis—Sorafenib—liver cancer	0.00663	0.00663	CcSEcCtD
Clindamycin—Redness—Doxorubicin—liver cancer	0.00636	0.00636	CcSEcCtD
Clindamycin—Seborrhoeic dermatitis—Doxorubicin—liver cancer	0.0063	0.0063	CcSEcCtD
Clindamycin—Vaginal haemorrhage—Epirubicin—liver cancer	0.00627	0.00627	CcSEcCtD
Clindamycin—Rash erythematous—Epirubicin—liver cancer	0.00606	0.00606	CcSEcCtD
Clindamycin—Fungal infection—Epirubicin—liver cancer	0.00601	0.00601	CcSEcCtD
Clindamycin—Erythema multiforme—Sorafenib—liver cancer	0.00596	0.00596	CcSEcCtD
Clindamycin—Abscess—Epirubicin—liver cancer	0.00587	0.00587	CcSEcCtD
Clindamycin—Flushing—Sorafenib—liver cancer	0.00585	0.00585	CcSEcCtD
Clindamycin—Rash pustular—Epirubicin—liver cancer	0.00582	0.00582	CcSEcCtD
Clindamycin—Vaginal haemorrhage—Doxorubicin—liver cancer	0.0058	0.0058	CcSEcCtD
Clindamycin—Stinging—Epirubicin—liver cancer	0.00573	0.00573	CcSEcCtD
Clindamycin—Rash erythematous—Doxorubicin—liver cancer	0.00561	0.00561	CcSEcCtD
Clindamycin—Fungal infection—Doxorubicin—liver cancer	0.00556	0.00556	CcSEcCtD
Clindamycin—Erythema—Sorafenib—liver cancer	0.00549	0.00549	CcSEcCtD
Clindamycin—Abscess—Doxorubicin—liver cancer	0.00543	0.00543	CcSEcCtD
Clindamycin—Rash pustular—Doxorubicin—liver cancer	0.00538	0.00538	CcSEcCtD
Clindamycin—Dysgeusia—Sorafenib—liver cancer	0.00538	0.00538	CcSEcCtD
Clindamycin—Stinging—Doxorubicin—liver cancer	0.0053	0.0053	CcSEcCtD
Clindamycin—Muscle spasms—Sorafenib—liver cancer	0.00528	0.00528	CcSEcCtD
Clindamycin—Anaemia—Sorafenib—liver cancer	0.00507	0.00507	CcSEcCtD
Clindamycin—Oliguria—Epirubicin—liver cancer	0.00504	0.00504	CcSEcCtD
Clindamycin—Leukopenia—Sorafenib—liver cancer	0.00491	0.00491	CcSEcCtD
Clindamycin—Ulcer—Epirubicin—liver cancer	0.00491	0.00491	CcSEcCtD
Clindamycin—Inflammation—Epirubicin—liver cancer	0.00479	0.00479	CcSEcCtD
Clindamycin—Hypertension—Sorafenib—liver cancer	0.00474	0.00474	CcSEcCtD
Clindamycin—Oliguria—Doxorubicin—liver cancer	0.00466	0.00466	CcSEcCtD
Clindamycin—Vaginal inflammation—Epirubicin—liver cancer	0.00464	0.00464	CcSEcCtD
Clindamycin—Dermatitis contact—Epirubicin—liver cancer	0.00459	0.00459	CcSEcCtD
Clindamycin—Ulcer—Doxorubicin—liver cancer	0.00454	0.00454	CcSEcCtD
Clindamycin—Anaphylactic shock—Sorafenib—liver cancer	0.00448	0.00448	CcSEcCtD
Clindamycin—Colitis—Epirubicin—liver cancer	0.00446	0.00446	CcSEcCtD
Clindamycin—Candida infection—Epirubicin—liver cancer	0.00443	0.00443	CcSEcCtD
Clindamycin—Skin exfoliation—Epirubicin—liver cancer	0.00443	0.00443	CcSEcCtD
Clindamycin—Inflammation—Doxorubicin—liver cancer	0.00443	0.00443	CcSEcCtD
Clindamycin—Thrombocytopenia—Sorafenib—liver cancer	0.00439	0.00439	CcSEcCtD
Clindamycin—Vaginal infection—Epirubicin—liver cancer	0.00438	0.00438	CcSEcCtD
Clindamycin—Vaginal inflammation—Doxorubicin—liver cancer	0.00429	0.00429	CcSEcCtD
Clindamycin—Dermatitis contact—Doxorubicin—liver cancer	0.00424	0.00424	CcSEcCtD
Clindamycin—Oesophagitis—Epirubicin—liver cancer	0.00424	0.00424	CcSEcCtD
Clindamycin—Rash maculo-papular—Epirubicin—liver cancer	0.00422	0.00422	CcSEcCtD
Clindamycin—Colitis—Doxorubicin—liver cancer	0.00412	0.00412	CcSEcCtD
Clindamycin—Candida infection—Doxorubicin—liver cancer	0.0041	0.0041	CcSEcCtD
Clindamycin—Skin exfoliation—Doxorubicin—liver cancer	0.0041	0.0041	CcSEcCtD
Clindamycin—Vaginal infection—Doxorubicin—liver cancer	0.00405	0.00405	CcSEcCtD
Clindamycin—Dyspnoea—Sorafenib—liver cancer	0.00399	0.00399	CcSEcCtD
Clindamycin—Dyspepsia—Sorafenib—liver cancer	0.00394	0.00394	CcSEcCtD
Clindamycin—Oesophagitis—Doxorubicin—liver cancer	0.00392	0.00392	CcSEcCtD
Clindamycin—Rash maculo-papular—Doxorubicin—liver cancer	0.0039	0.0039	CcSEcCtD
Clindamycin—Thrombophlebitis—Epirubicin—liver cancer	0.00389	0.00389	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00387	0.00387	CcSEcCtD
Clindamycin—Fatigue—Sorafenib—liver cancer	0.00386	0.00386	CcSEcCtD
Clindamycin—Constipation—Sorafenib—liver cancer	0.00383	0.00383	CcSEcCtD
Clindamycin—Pain—Sorafenib—liver cancer	0.00383	0.00383	CcSEcCtD
Clindamycin—Gastrointestinal pain—Sorafenib—liver cancer	0.00366	0.00366	CcSEcCtD
Clindamycin—Thrombophlebitis—Doxorubicin—liver cancer	0.0036	0.0036	CcSEcCtD
Clindamycin—Dermatitis exfoliative—Epirubicin—liver cancer	0.00357	0.00357	CcSEcCtD
Clindamycin—Urticaria—Sorafenib—liver cancer	0.00356	0.00356	CcSEcCtD
Clindamycin—Abdominal pain—Sorafenib—liver cancer	0.00354	0.00354	CcSEcCtD
Clindamycin—Body temperature increased—Sorafenib—liver cancer	0.00354	0.00354	CcSEcCtD
Clindamycin—Dermatitis bullous—Epirubicin—liver cancer	0.00353	0.00353	CcSEcCtD
Clindamycin—Anaphylactoid reaction—Epirubicin—liver cancer	0.00348	0.00348	CcSEcCtD
Clindamycin—Dermatitis exfoliative—Doxorubicin—liver cancer	0.0033	0.0033	CcSEcCtD
Clindamycin—Hypersensitivity—Sorafenib—liver cancer	0.0033	0.0033	CcSEcCtD
Clindamycin—Dermatitis bullous—Doxorubicin—liver cancer	0.00326	0.00326	CcSEcCtD
Clindamycin—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00322	0.00322	CcSEcCtD
Clindamycin—Asthenia—Sorafenib—liver cancer	0.00321	0.00321	CcSEcCtD
Clindamycin—Cardiac arrest—Epirubicin—liver cancer	0.0032	0.0032	CcSEcCtD
Clindamycin—Pruritus—Sorafenib—liver cancer	0.00317	0.00317	CcSEcCtD
Clindamycin—Dry skin—Epirubicin—liver cancer	0.00309	0.00309	CcSEcCtD
Clindamycin—Abdominal pain upper—Epirubicin—liver cancer	0.00308	0.00308	CcSEcCtD
Clindamycin—Diarrhoea—Sorafenib—liver cancer	0.00307	0.00307	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00303	0.00303	CcSEcCtD
Clindamycin—Cardiac arrest—Doxorubicin—liver cancer	0.00296	0.00296	CcSEcCtD
Clindamycin—Dizziness—Sorafenib—liver cancer	0.00296	0.00296	CcSEcCtD
Clindamycin—Abdominal distension—Epirubicin—liver cancer	0.00293	0.00293	CcSEcCtD
Clindamycin—Eosinophilia—Epirubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Clindamycin—Dry skin—Doxorubicin—liver cancer	0.00286	0.00286	CcSEcCtD
Clindamycin—Vomiting—Sorafenib—liver cancer	0.00285	0.00285	CcSEcCtD
Clindamycin—Abdominal pain upper—Doxorubicin—liver cancer	0.00285	0.00285	CcSEcCtD
Clindamycin—Rash—Sorafenib—liver cancer	0.00283	0.00283	CcSEcCtD
Clindamycin—Dermatitis—Sorafenib—liver cancer	0.00282	0.00282	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00281	0.00281	CcSEcCtD
Clindamycin—Headache—Sorafenib—liver cancer	0.00281	0.00281	CcSEcCtD
Clindamycin—Dysuria—Epirubicin—liver cancer	0.00272	0.00272	CcSEcCtD
Clindamycin—Neutropenia—Epirubicin—liver cancer	0.00272	0.00272	CcSEcCtD
Clindamycin—Abdominal distension—Doxorubicin—liver cancer	0.00271	0.00271	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Epirubicin—liver cancer	0.00271	0.00271	CcSEcCtD
Clindamycin—Eosinophilia—Doxorubicin—liver cancer	0.00267	0.00267	CcSEcCtD
Clindamycin—Nausea—Sorafenib—liver cancer	0.00266	0.00266	CcSEcCtD
Clindamycin—Photosensitivity reaction—Epirubicin—liver cancer	0.00266	0.00266	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00257	0.00257	CcSEcCtD
Clindamycin—Jaundice—Epirubicin—liver cancer	0.00253	0.00253	CcSEcCtD
Clindamycin—Urinary tract infection—Epirubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Clindamycin—Dysuria—Doxorubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Clindamycin—Neutropenia—Doxorubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Doxorubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Clindamycin—Photosensitivity reaction—Doxorubicin—liver cancer	0.00246	0.00246	CcSEcCtD
Clindamycin—Epistaxis—Epirubicin—liver cancer	0.00245	0.00245	CcSEcCtD
Clindamycin—Agranulocytosis—Epirubicin—liver cancer	0.00242	0.00242	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Clindamycin—Jaundice—Doxorubicin—liver cancer	0.00234	0.00234	CcSEcCtD
Clindamycin—Urinary tract infection—Doxorubicin—liver cancer	0.00234	0.00234	CcSEcCtD
Clindamycin—Epistaxis—Doxorubicin—liver cancer	0.00227	0.00227	CcSEcCtD
Clindamycin—Agranulocytosis—Doxorubicin—liver cancer	0.00224	0.00224	CcSEcCtD
Clindamycin—Erythema multiforme—Epirubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Clindamycin—Flushing—Epirubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Clindamycin—Erythema multiforme—Doxorubicin—liver cancer	0.00204	0.00204	CcSEcCtD
Clindamycin—Erythema—Epirubicin—liver cancer	0.00203	0.00203	CcSEcCtD
Clindamycin—Flushing—Doxorubicin—liver cancer	0.002	0.002	CcSEcCtD
Clindamycin—Flatulence—Epirubicin—liver cancer	0.002	0.002	CcSEcCtD
Clindamycin—Dysgeusia—Epirubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Clindamycin—Back pain—Epirubicin—liver cancer	0.00196	0.00196	CcSEcCtD
Clindamycin—Muscle spasms—Epirubicin—liver cancer	0.00195	0.00195	CcSEcCtD
Clindamycin—Erythema—Doxorubicin—liver cancer	0.00188	0.00188	CcSEcCtD
Clindamycin—Anaemia—Epirubicin—liver cancer	0.00188	0.00188	CcSEcCtD
Clindamycin—Flatulence—Doxorubicin—liver cancer	0.00185	0.00185	CcSEcCtD
Clindamycin—Dysgeusia—Doxorubicin—liver cancer	0.00184	0.00184	CcSEcCtD
Clindamycin—Vertigo—Epirubicin—liver cancer	0.00182	0.00182	CcSEcCtD
Clindamycin—Leukopenia—Epirubicin—liver cancer	0.00182	0.00182	CcSEcCtD
Clindamycin—Back pain—Doxorubicin—liver cancer	0.00182	0.00182	CcSEcCtD
Clindamycin—Muscle spasms—Doxorubicin—liver cancer	0.0018	0.0018	CcSEcCtD
Clindamycin—Hypertension—Epirubicin—liver cancer	0.00175	0.00175	CcSEcCtD
Clindamycin—Anaemia—Doxorubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Clindamycin—Discomfort—Epirubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Clindamycin—Vertigo—Doxorubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Clindamycin—Leukopenia—Doxorubicin—liver cancer	0.00168	0.00168	CcSEcCtD
Clindamycin—Anaphylactic shock—Epirubicin—liver cancer	0.00166	0.00166	CcSEcCtD
Clindamycin—Thrombocytopenia—Epirubicin—liver cancer	0.00162	0.00162	CcSEcCtD
Clindamycin—Hypertension—Doxorubicin—liver cancer	0.00162	0.00162	CcSEcCtD
Clindamycin—Discomfort—Doxorubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Clindamycin—Hypotension—Epirubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Clindamycin—Anaphylactic shock—Doxorubicin—liver cancer	0.00153	0.00153	CcSEcCtD
Clindamycin—Thrombocytopenia—Doxorubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Clindamycin—Dyspnoea—Epirubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Clindamycin—Dyspepsia—Epirubicin—liver cancer	0.00146	0.00146	CcSEcCtD
Clindamycin—Hypotension—Doxorubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Epirubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Clindamycin—Fatigue—Epirubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Clindamycin—Pain—Epirubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Clindamycin—Constipation—Epirubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Clindamycin—Dyspnoea—Doxorubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Clindamycin—Gastrointestinal pain—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Clindamycin—Dyspepsia—Doxorubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Clindamycin—Fatigue—Doxorubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Clindamycin—Urticaria—Epirubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Clindamycin—Pain—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Clindamycin—Constipation—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Clindamycin—Body temperature increased—Epirubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Clindamycin—Abdominal pain—Epirubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Clindamycin—Gastrointestinal pain—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Clindamycin—Hypersensitivity—Epirubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Clindamycin—Urticaria—Doxorubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Clindamycin—Abdominal pain—Doxorubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Clindamycin—Body temperature increased—Doxorubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Clindamycin—Asthenia—Epirubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Clindamycin—Pruritus—Epirubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Clindamycin—Diarrhoea—Epirubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Clindamycin—Hypersensitivity—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Clindamycin—Asthenia—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Clindamycin—Dizziness—Epirubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Clindamycin—Pruritus—Doxorubicin—liver cancer	0.00108	0.00108	CcSEcCtD
Clindamycin—Vomiting—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Clindamycin—Diarrhoea—Doxorubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Clindamycin—Rash—Epirubicin—liver cancer	0.00104	0.00104	CcSEcCtD
Clindamycin—Dermatitis—Epirubicin—liver cancer	0.00104	0.00104	CcSEcCtD
Clindamycin—Headache—Epirubicin—liver cancer	0.00104	0.00104	CcSEcCtD
Clindamycin—Dizziness—Doxorubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Clindamycin—Nausea—Epirubicin—liver cancer	0.000984	0.000984	CcSEcCtD
Clindamycin—Vomiting—Doxorubicin—liver cancer	0.000974	0.000974	CcSEcCtD
Clindamycin—Rash—Doxorubicin—liver cancer	0.000966	0.000966	CcSEcCtD
Clindamycin—Dermatitis—Doxorubicin—liver cancer	0.000965	0.000965	CcSEcCtD
Clindamycin—Headache—Doxorubicin—liver cancer	0.00096	0.00096	CcSEcCtD
Clindamycin—Nausea—Doxorubicin—liver cancer	0.00091	0.00091	CcSEcCtD
